Product News You can check out the latest product information
-
Obtained Australian TGA approval for Allplex™ HPV HR Detection
Seegene has received approval from Australia’s Therapeutic Goods Administration for Allplex™ HPV HR Detection. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country.
Nov 17, 2022｜ Allplex™ HPV HR Detection
-
Obtained Australian TGA approval for Allplex™ HPV 28 Detection
Seegene has received approval from Australia’s Therapeutic Goods Administration for Allplex™ HPV28 Detection. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country.
Nov 17, 2022｜ Allplex™ HPV28 Detection
-
Obtained Australian TGA approval for Allplex™ stx1/2/2a/2d Typing
Seegene has received approval from Australia’s Therapeutic Goods Administration for Allplex™ stx1/2/2a/2d Typing. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country.
Oct 28, 2022｜ Allplex™ stx1/2/2a/2d Typing
-
Obtained Australian TGA approval for Allplex™ NG-DR Assay
Seegene has received approval from Australia’s Therapeutic Goods Administration for Allplex™ NG-DR Assay. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country.
Sep 14, 2022｜ Allplex™ NG & DR Assay
-
Obtained CE-IVDD marking for Allplex™ stx1/2/2a/2d Typing
Seegene has received CE-IVD mark under European Union on In Vitro Diagnostic for Allplex™ stx1/2/2a/2d Typing. Allplex™ stx1/2/2a/2d Typing provides screening and genotyping test not only for stx1 and stx2, but also the most potent types, stx2a and stx2d.
May 20, 2022｜ Allplex™ stx1/2/2a/2d Typing
-
Obtained CE-IVDD marking for Allplex™ HPV 28 Detection
Seegene has received CE-IVD mark under European Union on In Vitro Diagnostic for Allplex™ HPV28 Detection. Allplex™ HPV28 Detection is a multiplex real-time PCR assay that enables simultaneous amplification and detection of target nucleic acids of 19 high-risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82) and 9 low-risk HPV types (6, 11, 40, 42, 43, 44, 54, 61, 70) as well as Internal Control (IC)
May 20, 2022｜ Allplex™ HPV28 Detection
-
Obtained Australian TGA approval for Allplex™ SARS-CoV-2 fast PCR Assay
Seegene has received approval from Australia’s Therapeutic Goods Administration for Allplex™ SARS-CoV-2 fast PCR Assay. Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country.
Apr 12, 2022｜ Allplex™ SARS-CoV-2 fast PCR Assay
-
Obtained Australian TGA approval/European CE-IVD marking for Allplex™ RV Master Assay
Allplex™ RV Master Assay has received approval from Australia’s Therapeutic Goods Administration and achieved the European CE-IVD marking.Therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be supplied in the country. The CE-IVD marking is a legal requirement for marketing medical devices in the European Union.
Apr 01, 2022｜ Allplex™ RV Master Assay